---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-103316"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-08-28T21:11:48+00:00"
generated_at: "2026-08-28T21:14:10.154070+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Coherus Oncology enters ATM offering to sell up to $50M of common stock

## Summary
- Sales agreement dated Aug 28, 2026 with Leerink Partners LLC for at-the-market sales of common stock.
- Company may offer up to $50.0M aggregate gross proceeds; no obligation to sell any shares.
- Agent commission up to 3% of gross proceeds; customary indemnification provided.
- Proceeds intended for general corporate purposes including working capital.
- Offered under S-3 shelf (effective Dec 8, 2025) with prospectus supplement filed Aug 28, 2026.

## SEC filing metadata
- accession: 0001104659-26-103316
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-08-28T21:11:48+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/0001104659-26-103316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926103316/chrs-20260828x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-103316
- JSON: https://secwatch.observer/filing/0001104659-26-103316.json
- Plain text: https://secwatch.observer/filing/0001104659-26-103316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.